Fig. 3: Stratification by loss of heterozygosity (LOH). | Nature Communications

Fig. 3: Stratification by loss of heterozygosity (LOH).

From: Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy

Fig. 3

A No significant difference in HLA-LOH prevalence between high and low HLA-I Antigen Presentation Score (HAPS) subgroups in nine immune checkpoint inhibitor (ICI)-treated cohorts (n = 616) (Fisher’s exact test). Source data are provided as a Source Dat a file. B, C Left: We found a significant association between high HAPS and overall survival (OS) in patients with no HLA-LOH, with no association between high-HAPS and OS in patients with HLA-LOH. Right: We found a significant prolonged OS in patients with high HAPS and no LOH based on HAPS and HLA-LOH status (Kaplan–Meier analysis with the log-rank test). Source data are provided as a Source Data file. D Forest plot of OS differences between high and low HAPS subgroups according to the HLA-LOH status in training and validation cohorts (n = 320) (Kaplan–Meier analysis with the log-rank test). The error bars indicate 95%CI for HR. Source data are provided as a Source Data file. E, F Left: In the Wang cohort (Wang-Tissue or Wang-Blood), we found associations between high HAPS and OS in patients based on HLA-LOH status. Right: We found prolonged OS in patients with high HAPS and no LOH based on HAPS and HLA-LOH status (Kaplan–Meier analysis with the log-rank test). Source data are provided as a Source Data file.

Back to article page